Please login to the form below

Not currently logged in
Email:
Password:

Hikma appoints group scientific officer and global head of R&D

Dr Surendera Tyagi joins the pharma group from Fresenius Kabi

Speciality pharmaceutical group Hikma has appointed a group scientific officer and gloval head of R&D in the form of Dr Surendera Tyagi, who will focus on the group’s non-injectables business and will become a member of Hikma’s executive committee.

He joins the pharma group from Fresenius Kabi, where he most recently led its US innovation and development centre.

Prior to this, he served as chief scientific officer for Sabur Pharma, an oncology company that was acquired by Fresenius in 2008.

Tyagi has also held various scientific and regulatory roles at Roche IGEN, Abbott/Hospita and Scwarz Pharma.

He said: “Hikma’s track record of delivering affordable, quality medicines to people who need them is a purpose that I share, and I look forward to accelerating their R&D efforts by advancing and expanding their pipeline.”

22nd January 2018

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics